Zacks Research Issues Pessimistic Forecast for JNJ Earnings

Johnson & Johnson (NYSE:JNJ) – Analysts at Zacks Research dropped their Q1 2027 EPS estimates for shares of Johnson & Johnson in a research report issued on Thursday, January 8th. Zacks Research analyst Team now forecasts that the company will earn $2.89 per share for the quarter, down from their prior estimate of $2.90. The consensus estimate for Johnson & Johnson’s current full-year earnings is $10.58 per share. Zacks Research also issued estimates for Johnson & Johnson’s Q2 2027 earnings at $3.08 EPS, Q3 2027 earnings at $3.11 EPS, Q4 2027 earnings at $3.12 EPS and FY2027 earnings at $12.20 EPS.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS.

Other equities research analysts also recently issued reports about the stock. Johnson Rice set a $190.00 target price on shares of Johnson & Johnson and gave the company a “hold” rating in a research note on Wednesday, October 22nd. Daiwa America raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. Scotiabank started coverage on Johnson & Johnson in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $230.00 target price on the stock. Wells Fargo & Company increased their price objective on Johnson & Johnson from $212.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, December 12th. Finally, Royal Bank Of Canada set a $240.00 target price on Johnson & Johnson in a research note on Wednesday, December 17th. Four research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $213.33.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $204.47 on Friday. The stock’s 50-day simple moving average is $202.87 and its two-hundred day simple moving average is $184.52. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $215.18. The firm has a market capitalization of $492.62 billion, a P/E ratio of 19.74, a P/E/G ratio of 2.11 and a beta of 0.34. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a $1.30 dividend. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. Johnson & Johnson’s payout ratio is presently 50.19%.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of JNJ. Norges Bank purchased a new stake in Johnson & Johnson in the second quarter worth $4,877,174,000. Laurel Wealth Advisors LLC lifted its position in shares of Johnson & Johnson by 15,040.6% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 7,420,699 shares of the company’s stock worth $1,133,512,000 after purchasing an additional 7,371,687 shares during the period. Capital International Investors boosted its stake in shares of Johnson & Johnson by 545.6% during the 3rd quarter. Capital International Investors now owns 3,865,050 shares of the company’s stock valued at $716,657,000 after purchasing an additional 3,266,354 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Johnson & Johnson by 1.3% during the second quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock valued at $36,209,060,000 after buying an additional 3,085,180 shares during the period. Finally, Assenagon Asset Management S.A. increased its position in shares of Johnson & Johnson by 159.6% during the second quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock valued at $635,327,000 after buying an additional 2,557,388 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Barclays raised its JNJ price target on strength in key drugs, signaling analyst confidence in the company’s mid-term revenue drivers. Barclays Raises Johnson & Johnson (JNJ) Target on Strength in Key Drugs
• Positive Sentiment: Deal with the Trump administration gives JNJ tariff exemptions and accelerates a reported ~$55 billion plan to expand U.S. manufacturing — this reduces tariff risk, improves supply-chain resilience and could support margins over time. J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve
• Positive Sentiment: Clinical and product-development catalysts: mid-stage success for nipocalimab in SLE and J&J MedTech’s Ottava surgical robot submission to the FDA could drive future revenue and sentiment if approvals/commercialization progress. J&J succeeds in mid-stage trial for SLE therapy Johnson & Johnson MedTech submits Ottava surgical robot to FDA
• Neutral Sentiment: Sector tailwind: healthcare stocks have been rallying and JNJ sits in many health-care ETFs, which can provide passive-buying support independent of company-specific news. This ETF Is Proof That the Healthcare Rebound Is Real
• Neutral Sentiment: Partnerships and collaborations (e.g., Lexeo on cardiac gene therapy) expand J&J’s pipeline exposure but are longer-term and incremental to near-term earnings. Lexeo Therapeutics Announces Research Collaboration with Johnson & Johnson
• Negative Sentiment: JNJ agreed to cut U.S. drug prices as part of the government deal — that creates near- and medium-term revenue/price pressure for affected medicines and is a headline risk for investors focused on margins. Johnson & Johnson reaches deal with US government to lower drug prices
• Negative Sentiment: Zacks trimmed several near-term EPS estimates (Q1–Q4 and FY2027) marginally — this reflects some analyst caution after the pricing agreement and contributes to downward pressure on the stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.